Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2

Status

Completed 5Unknown 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 186Lymphoma, Large B-Cell, Diffuse 41Leukemia, Lymphocytic, Chronic, B-Cell 41Recurrence 28Neoplasms, Plasma Cell 27Lymphoma 25Lymphoma, Mantle-Cell 23Lymphoma, Follicular 23Leukemia 20Lymphoma, B-Cell, Marginal Zone 15Lymphoma, Non-Hodgkin 14Leukemia, Myeloid, Acute 13Smoldering Multiple Myeloma 9Myelodysplastic Syndromes 9Lymphoma, T-Cell, Peripheral 7Lymphoma, B-Cell 7Waldenstrom Macroglobulinemia 6Neoplasms 6Neoplasm, Residual 6Immunoglobulin Light-chain Amyloidosis 6Lymphoma, T-Cell 5Leukemia, Plasma Cell 5Leukemia, Myelomonocytic, Chronic 5Renal Insufficiency 4Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Hematologic Diseases 4Sezary Syndrome 3

Interventions

Dexamethasone 23Melphalan 18Cyclophosphamide 12Filgrastim 10Bortezomib 10Calcium Dobesilate 8Peripheral Blood Stem Cell Transplantation 7daratumumab 6Lenalidomide 6pomalidomide 5dexamethasone acetate 3birtamimab 3Thalidomide 3Radiotherapy 3Interferon-alpha 3Granulocyte Colony-Stimulating Factor 3sargramostim 2isatuximab 2dexamethasone 21-phosphate 2belantamab mafodotin 2Focal Adhesion Protein-Tyrosine Kinases 2Etoposide 2Epoetin Alfa 2Doxycycline 2Busulfan 2siltuximab 1pegfilgrastim 1ixazomib 1fludarabine phosphate 1elotuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Immunoglobulin Light-chain Amyloidosis × Lenalidomide × Clear all
NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Barbara Ann Karmanos Cancer Institute

Phase 2 Unknown
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT01194791 2017-04-25

LENDEXAL

PETHEMA Foundation

Phase 2 Completed
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT00091260 2017-02-20

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Boston Medical Center

Phase 2 Completed
82 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT00679367 2017-02-20

MRD

Boston Medical Center

Phase 2 Completed
16 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT00883623 2013-11-25

LEOMEX

Heidelberg University

Phase 2 Completed
50 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT00564889 2013-05-14

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Mayo Clinic

Phase 2 Completed
35 enrolled 11 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡